Categories
rss

WHO: Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19)

Murilo Freitas - 09:46, 26 de March de 20201,122

This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It is intended for blood services, national health authorities, and others responsible for the provision of blood and blood components and integration of the blood system within the public health system. WHO will continue to update this guidance as new information becomes available.

Please, go to https://apps.who.int/iris/rest/bitstreams/1272656/retrieve

 

REFERENCE NUMBERS

WHO REFERENCE NUMBER: WHO/2019-nCoV/BloodSupply/2020.1
COPYRIGHT
CC BY-NC-SA 3.0 IGO

 

 
Categories
rss

PAHO: Ethics guidance on issues raised by the novel coronavirus disease (COVID-19) pandemic 

Fernanda Lessa - 08:52, 26 de March de 20201,071

 

PAHO’s Regional Program on Bioethics has developed a document that provides ethics guidance for the public health response, health care delivery and research during current COVID-19 pandemic.

Such document is available at: https://www.paho.org/en/documents/ethics-guidance-issues-raised-novel-coronavirus-disease-covid-19-pandemic.

In the virtual seminar to PAHO’s ethics guidance for COVID-19 research was presented the imperatives to conduct rapid ethics review of COVID-19 research protocols and to promote future research through the use of broad consent were discussed.  The recording is available at: https://paho.webex.com/recordingservice/sites/paho/recording/718eb53feb6b4ba1abe8529be1b96586

 
Categories
rss

FDA: Investigational COVID-19 Convalescent Plasma – Emergency Investigational New Drug Applications

Fernanda Lessa - 08:39, 25 de March de 20201,029

Investigational COVID-19 Convalescent Plasma – Emergency INDs

FDA is facilitating access to COVID-19 convalescent plasma for use in patients with serious or immediately life-threatening COVID-19 infections through the process of single patient emergency Investigational New Drug Applications (eINDs) for Individual patients under 21 CFR 312.310. This process allows the use of an investigational drug for the treatment of an individual patient by a licensed physician upon FDA authorization. This does not include the use of COVID-19 convalescent plasma for the prevention of infection.

Click here to access the complete information.

 
Categories
rss

Voluntary Nationwide Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening

Fernanda Lessa - 04:00, 25 de March de 2020803
Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level.
Additional information:

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-laboratories-issues-voluntary-nationwide-recall-phytonadione-injectable-emulsion-usp-10

 
Categories
rss

FDA: Fecal Microbiota for Transplantation: Safety Alert – Regarding Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19

Fernanda Lessa - 16:00, 22 de March de 20201,478
FDA is informing health care providers and patients of the potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation (FMT)

http://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-regarding-additional-safety-protections-pertaining

 
Categories
Home Posts

WHO: There is a lot of false information around… These are the facts!

Fernanda Lessa - 19:14, 21 de March de 20201,469

These are the facts:

🔢 People of all ages CAN be infected by the coronavirus. Older people, and people with pre-existing medical conditions (such as asthma, diabetes, heart disease) appear to be more vulnerable to becoming severely ill with the virus.

❄️ Cold weather and snow CANNOT kill the coronavirus.

☀️ The coronavirus CAN be transmitted in areas with hot and humid climates

🦟 The coronavirus CANNOT be transmitted through mosquito bites.

🐶 There is NO evidence that companion animals/pets such as dogs or cats can transmit the coronavirus.

🛀 Taking a hot bath DOES NOT prevent the coronavirus

💨 Hand dryers are NOT effective in killing the coronavirus

🟣 Ultraviolet light SHOULD NOT be used for sterilization and can cause skin irritation

🌡️ Thermal scanners CAN detect if people have a fever but CANNOT detect whether or not someone has the coronavirus

💦 Spraying alcohol or chlorine all over your body WILL NOT kill viruses that have already entered your body

💉 Vaccines against pneumonia, such as pneumococcal vaccine and _Haemophilus influenzae_ type b (Hib) vaccine, DO NOT provide protection against the coronavirus.

👃 There is NO evidence that regularly rinsing the nose with saline has protected people from infection with the coronavirus.

🧄 Garlic is healthy but there is NO evidence from the current outbreak that eating garlic has protected people from the coronavirus.

💊 Antibiotics DO NOT work against viruses, antibiotics only work against bacteria.

🧪 To date, there is specific medicine recommended to prevent or treat the coronavirus.

 

Check the facts on the WHO website: click here

 

 

 
Categories
rss

PAHO: Clinical trials of drug repositioning for COVID-19 treatment

Murilo Freitas - 20:48, 20 de March de 2020715
Rosa and Santos

The World Health Organization (WHO) was informed in December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants’ clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.

Article’s language
English
https://www.paho.org/journal/sites/default/files/2020-03/40-20-249-Rosa-prelim…
 
Categories
rss

Coronavirus (COVID-19) Update: FDA Alerts Consumers About Unauthorized Fraudulent COVID-19 Test Kits

Murilo Freitas - 20:43, 20 de March de 2020626
For Immediate Release:
Statement From:
Commissioner of Food and Drugs – Food and Drug Administration

Stephen M. Hahn M.D.

Associate Commissioner for Regulatory Affairs – Office of Regulatory Affairs

Judith A. McMeekin Pharm.D.

The U.S. Food and Drug Administration is actively and aggressively monitoring the market for any firms marketing products with fraudulent coronavirus (COVID-19) diagnostic, prevention and treatment claims as part of our ongoing efforts to protect public health during this pandemic. As a result of these activities, the agency is beginning to see unauthorized fraudulent test kits that are being marketed to test for COVID-19 in the home.

For more information go to

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-alerts-consumers-about-unauthorized-fraudulent-covid-19-test-kits

 
PRAIS 2.0